Circulating Factors in Nephrotic Syndrome
NCT06315504
Autoimmune Diseases, Female Urogenital Diseases
View Trial DetailsNCT Number: NCT07785739
This prospective observational study aims to evaluate predictors of disease progression in patients with primary membranous nephropathy and to assess the performance of a prognostic nomogram in predicting renal outcomes in the Egyptian population.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Primary membranous nephropathy (pMN) is a leading cause of nephrotic syndrome in adults. Its clinical course is highly variable, ranging from spontaneous remission to progressive kidney function decline and end-stage kidney disease. Current prognostic assessment relies mainly on conventional clinical and laboratory parameters such as proteinuria, serum creatinine, estimated glomerular filtration rate (eGFR), and serum albumin. These markers have limited accuracy in predicting individual patient outcomes.
Several prognostic nomograms have been developed by combining clinical, laboratory, and immunological variables. However, most of these models were derived from single-center cohorts and require external validation in different populations.
This prospective observational study will evaluate clinical and laboratory predictors of disease progression in patients with biopsy-proven primary membranous nephropathy and assess the performance of a prognostic nomogram for predicting renal outcomes in patients attending Assiut University Hospitals.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Ability of the prognostic nomogram to predict disease progression in patients with primary membranous nephropathy, assessed by the area under the receiver operating characteristic curve (AUC).
Time frame: 6 months
Identification of independent clinical and laboratory predictors of disease progression in primary membranous nephropathy using multivariable analysis
Time frame: 6 months
Change in estimated glomerular filtration rate (eGFR) from baseline, measured in mL/min/1.73 m².
Time frame: 6 month
Proportion of patients achieving complete or partial remission according to KDIGO criteria
Time frame: 6 months
Validation of the predictive performance of the prognostic nomogram in the local patient population using discrimination and calibration metrics
Contact information is provided by the study sponsor or research team.
Assiut University
Other
Assessment of a Clinical Prediction Model for Disease Progression in Patients With Primary Membranous Nephropathy: A Prospective Observational Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06315504
Autoimmune Diseases, Female Urogenital Diseases
View Trial DetailsNCT03949855
Autoimmune Diseases, Female Urogenital Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05505500
Autoimmune Diseases, Disease
Ann Arbor, Michigan, United States
View Trial DetailsNCT04278729
Autoimmune Diseases, Female Urogenital Diseases
Chapel Hill, North Carolina, United States
View Trial Details